NASDAQ:CLNN Clene (CLNN) Stock Price, News & Analysis $6.70 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.68 -0.02 (-0.27%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Clene Stock (NASDAQ:CLNN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Clene alerts:Sign Up Key Stats Today's Range$6.55▼$6.9050-Day Range$4.71▼$7.3952-Week Range$2.28▼$13.50Volume106,520 shsAverage Volume1.35 million shsMarket Capitalization$85.63 millionP/E RatioN/ADividend YieldN/APrice Target$33.25Consensus RatingModerate Buy Company Overview Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments. Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS). Early-stage studies have explored safety, tolerability, and preliminary signals of biological activity, while ongoing Phase 2 trials aim to evaluate efficacy endpoints in patient populations. The company has also initiated trials in spinal cord injury to investigate broader applications of its nanoparticle technology in central nervous system repair and protection. Headquartered in Salt Lake City, Utah, Clene maintains research and development operations in the United States and collaborates with academic institutions and clinical sites across North America and Australia. These partnerships support its translational research efforts and enable access to patient cohorts for clinical investigation. Clene has secured manufacturing capabilities for its nanoparticle formulations and is working to scale production processes in anticipation of later-stage clinical studies and potential commercialization. Clene is led by a management team with experience in biotechnology development, neuroscience research, and clinical operations. The company continues to expand its leadership bench through strategic hires and external collaborations, with the goal of advancing its pipeline of nanoparticle therapeutics toward regulatory approval and broader patient access.AI Generated. May Contain Errors. Read More Clene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreCLNN MarketRank™: Clene scored higher than 71% of companies evaluated by MarketBeat, and ranked 212th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingClene has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialClene has a consensus price target of $33.25, representing about 396.3% upside from its current price of $6.70.Amount of Analyst CoverageClene has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Clene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Clene are expected to grow in the coming year, from ($1.58) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clene is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clene is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.36% of the float of Clene has been sold short.Short Interest Ratio / Days to CoverClene has a short interest ratio ("days to cover") of 11.47, which indicates bearish sentiment.Change versus previous monthShort interest in Clene has recently decreased by 0.21%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClene does not currently pay a dividend.Dividend GrowthClene does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.67 News SentimentClene has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Clene this week, compared to 4 articles on an average week.Search Interest12 people have searched for CLNN on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows7 people have added Clene to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Clene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,043,481.00 in company stock.Percentage Held by Insiders28.30% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions23.28% of the stock of Clene is held by institutions.Read more about Clene's insider trading history. Receive CLNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLNN Stock News HeadlinesClene Extends Debt Maturities and Strengthens Cash RunwayMay 14, 2026 | tipranks.comClene (NASDAQ:CLNN) Major Shareholder Sells $149,694.75 in StockMay 14, 2026 | insidertrades.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered. | Weiss Ratings (Ad)Clene Reports First Quarter 2026 Financial Results and Recent Operating HighlightsMay 14, 2026 | globenewswire.comClene Announces $7 Million Registered Direct Equity OfferingMay 11, 2026 | theglobeandmail.comClene (NASDAQ:CLNN) Major Shareholder Sells $34,827.95 in StockMay 6, 2026 | insidertrades.comAnalysts Offer Insights on Consumer Goods Companies: Clene (CLNN) and Colgate-Palmolive (CL)May 5, 2026 | theglobeandmail.comClene (NASDAQ:CLNN) Major Shareholder Sells $34,874.88 in StockMay 1, 2026 | insidertrades.comSee More Headlines CLNN Stock Analysis - Frequently Asked Questions How have CLNN shares performed this year? Clene's stock was trading at $5.87 on January 1st, 2026. Since then, CLNN shares have increased by 14.1% and is now trading at $6.70. How were Clene's earnings last quarter? Clene Inc. (NASDAQ:CLNN) posted its earnings results on Thursday, May, 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.05. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. When did Clene's stock split? Clene shares reverse split before market open on Thursday, July 11th 2024.The 1-20 reverse split was announced on Thursday, July 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Clene? Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Clene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clene investors own include Waste Connections (WCN), AUO (AUOTY), Voyager Therapeutics (VYGR), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/14/2026Today5/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, CLNN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLNN CIK1822791 Webclene.com Phone801-676-9695FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Clene$33.25 High Price Target$48.00 Low Price Target$23.00 Potential Upside/Downside+396.3%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.17 million Net Margins-25,009.70% Pretax Margin-25,009.70% Return on EquityN/A Return on Assets-137.98% Debt Debt-to-Equity RatioN/A Current Ratio1.94 Quick Ratio1.93 Sales & Book Value Annual Sales$200 thousand Price / Sales428.13 Cash FlowN/A Price / Cash FlowN/A Book Value($1.47) per share Price / Book-4.56Miscellaneous Outstanding Shares12,780,000Free Float9,162,000Market Cap$85.63 million OptionableNo Data Beta0.89 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:CLNN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
